Physiologic insulin replacement in type 2 diabetes: Optimizing postprandial glucose control

Diabetes Educator

Volumn 32, Issue 3, 2006, Pages 423-432

  Robertson, Carolyn ^a  

^a Diabetes Team Associates   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; INSULIN;

BLOOD; CLINICAL TRIAL; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; POSTPRANDIAL STATE; REVIEW; RISK FACTOR;

BLOOD GLUCOSE; CLINICAL TRIALS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; POSTPRANDIAL PERIOD; RISK FACTORS;

EID: 33744507447     PISSN: 01457217     EISSN: 15546063     Source Type: Journal    
DOI: 10.1177/0145721706288255     Document Type: Review

References (52)

1. Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in the United States. Available at: http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2003.pdf. Accessed September 14, 2005.
2. DeWitt DE, Dugdale DC. Using new insulin strategies in the outpatient treatment of diabetes: clinical applications. JAMA. 2003;289:2265-2269.
3. DeWitt DE, Hirsch IB. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review. JAMA. 2003,289:2254-2264.
4. Funnell MM, Kruger DF, Spencer M. Self-management support for insulin therapy in type 2 diabetes. Diabetes Educ. 2004,30:274-280.
5. Wallace TM, Matthews DR. Poor glycaemic control in type 2 diabetes: a conspiracy of disease, suboptimal therapy and attitude. QJM. 2000,93:369-374.
6. Salgo P, moderator. Paradigm shifts in diabetes management. 2003. Available at: 2005.
7. Parkin CG, Brooks N. Is Postprandial Glucose Control Important? Is It Practical In Primary Care Settings? Clinical Diabetes. 2002,20:71-76.
8. Del Prato S, Marchetti P, Bonadonna RC. Phasic insulin release and metabolic regulation in type 2 diabetes. Diabetes. 2002, 51(suppl 1):S109-S116.
9. American Diabetes Association. Postprandial blood glucose. Diabetes Care. 2001,24:775-778.
10. White JR Jr, Campbell RK, Hirsch IB. Novel insulins and strict glycemic control: analogues approximate normal insulin secretory response. Postgrad Med [serial online]. 2003;113. Available at: www.postgradmed.com/issue/2003/06_03/ 1white.htm. Accessed October 11, 2004.
11. Mitrakou A, Kelley D, Veneman T, et al. Contribution of abnormal muscle and liver glucose metabolism to postprandial hyperglycemia in NIDDM. Diabetes. 1990,39:1381-1390.
12. Bonora E, Calcaterra F, Lombardi S, et al. Plasma glucose levels throughout the day and HbA(1c) interrelationships in type 2 diabetes: implications for treatment and monitoring of metabolic control. Diabetes Care. 2001;24:2023-2029.
13. Kelley D. Approaches to preventing prandial hyperglycemic excursions. Endocrinol Diabetes. 1999,6:S7-S11.
14. Palumbo PJ. Gycemic control, mealtime glucose excursions, and diabetic complications in type 2 diabetes mellitus. Mayo Clin Proc. 2001;76:609-618.
15. Mayfield JA, White RD. Insulin therapy for type 2 diabetes: rescue, augmentation, and replacement of beta-cell function. Am Fam Physician. 2004;70:489-500.
16. Carroll MF, Gutierrez A, Castro M, Tsewang D, Schade DS. Targeting postprandial hyperglycemia: a comparative study of insulinotropic agents in type 2 diabetes. J Clin Endocrinol Metab. 2003,88:5248-5254.
17. Avignon A, Radauceanu A, Monnier L. Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes. Diabetes Care. 1997;20:1822-1826.
18. Avignon A, Radauceanu A, Monnier L. Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes. Diabetes Care. 1997,20:1822-1826.
19. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes epidemiology: collaborative analysis of diagnostic criteria in Europe. Lancet. 1999;354:617-621.
20. Feinglos MN, Thacker CH, English J, Bethel MA, Lane JD. Modification of postprandial hyperglycemia with insulin lispro improves glucose control in patients with type 2 diabetes. Diabetes Care. 1997;20:1539-1542.
21. Donahue RP, Abbott RD, Reed DM, Yano K. Postchallenge glucose concentration and coronary heart disease in men of Japanese ancestry. Honolulu Heart Program. Diabetes. 1987;36:689-692.
22. Bonora E. Postprandial peaks as a risk factor for cardiovascular disease: epidemiological perspectives. Int J Clin Pract Suppl. 2002;129:5-11.
23. Bastyr E Jr, Stuart CA, Brodows RG, et al. Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c. IOEZ Study Group. Diabetes Care. 2000;23:1236-1241.
24. Dimitriadis GD, Gerich JE. Importance of timing of preprandial subcutaneous insulin administration in the management of diabetes mellitus. Diabetes Care. 1983,6:374-377.
25. Mudaliar SR, Mohideen P, Baxi SC, et al. Pharmacodynamic and pharmacokinetic properties of a premixed 85/15 human insulin preparation. Clin Ther. 2001;23:404-412.
26. Heller S. Reducing hypoglycaemia with insulin analogues. Int J Obes Relat Metab Disord. 2002,26(suppl 3):S31-S36.
27. Hollander P. Premixed insulins: how do they compare with other insulin preparations? Postgrad Med. 1991;89:52-61.
28. Heinemann L, Linkeschova R, Rave K, Hompesch B, Sedlak M, Heise T. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care. 2000;23:644-649.
29. Hershon KS, Blevins TC. Once-daily insulin glargine compared with twice-daily NPH insulin in patients with type 1 diabetes. Endocr Pract. 2004;10:10-17.
30. Rosenstock J, Park G, Zimmerman J. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. US Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group. Diabetes Care. 2000;23:1137-1142.
31. Rosenstock J, Schwartz SL, Clark CM Jr, Park GD, Donley DW, Edwards MB. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care. 2001;24:631-636.
32. Levemir insulin detemir injection [package insert]. Princeton, NJ: Novo Nordisk Pharmaceuticals; 2005.
33. Retnakaran R. Using insulin effecitvely in the management of diabetes. Endocr Rounds. 2004;4:3203.
34. Novolog insulin aspart (rDNA origin) injection [package insert]. Princeton, NJ: Novo Nordisk Pharmaceuticals; 2004.
35. Humalog insulin lispro injection [package insert]. Indianapolis, Ind: Eli Lilly and Company; 2004.
36. Apidra insulin glulisine (rDNA origin) injection [package insert]. Kansas City, Mo: Aventis Pharmaceuticals; 2004.
37. Anderson JH Jr, Brunelle RL, Keohane P, et al. Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Multicenter Insulin Lispro Study Group. Arch Intern Med. 1997;157:1249-1255.
38. Gale EA. A randomized, controlled trial comparing insulin lispro with human soluble insulin in patients with type 1 diabetes on intensified insulin therapy. The UK Trial Group. Diabet Med. 2000;17:209-214.
39. Raskin P, Guthrie RA, Leiter L, Riis A, Jovanovic L. Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes. Diabetes Care. 2000;23:583-588.
40. Dailey G, Rosenstock J, Moses RG, Ways K. Insulin glulisine provides improved glycemic control in patients with type 2 diabetes. Diabetes Care. 2004;27:2363-2368.
41. Dreyer M, Prager R, Robinson A, Busch K, Souhami E. Efficacy and safety of insulin glulisine (GLU) and insulin lispro (IL), combined with insulin glargine (GLAR) in patients with type 1 diabetes. Diabetes. 2004;53:A123.
42. Nosek L, Becker RHA, Frick AD, Kapitza C, Heise T, Rave K. Prandial blood glucose control with pre- and post-meal insulin glulisine versus regular human insulin. Diabetes. 2004;53:A139-A140.
43. Garg S, Rosenstock J, Ways K. Insulin dose and weight profiles of pre- and post-meal insulin glulisine (GLU) in a basal-bolus regimen with insulin glargine in patients with type 1 diabetes. Diabetes. 2004;53:A125-A126.
44. Woolf SH, Davidson MB, Greenfield S, et al. Controlling blood glucose levels in patients with type 2 diabetes mellitus: an evidence-based policy statement by the American Academy of Family Physicians and American Diabetes Association. J Fam Pract. 2000;49:453-460.
45. Levemir insulin detemir (rDNA orgin) injection [package insert]. Princeton, NJ: Novo Nordisk Pharmaceuticals; 2005.
46. Lantus insulin glargine (rDNA origin) injection [package insert]. Kansas City, Mo: Aventis Pharmaceuticals; 2004.
47. Overmann H, Heinemann L. Injection-meal interval: recommendations of diabetologists and how patients handle it. Diabetes Res Clin Pract. 1999;43:137-142.
48. Heinemann L. Do insulin-treated diabetic patients use an injection-meal-interval in daily life? Diabet Med. 1995;12:449-450.
49. Hedman CA, Lindstrom T, Arnqvist HJ. Direct comparison of insulin lispro and aspart shows small differences in plasma insulin profiles after subcutaneous injection in type 1 diabetes. Diabetes Care. 2001;24:1120-1121.
50. Home PD, Lindholm A, Hylleberg B, Round P. Improved glycemic control with insulin aspart: a multicenter randomized double-blind crossover trial in type 1 diabetic patients. UK Insulin Aspart Study Group. Diabetes Care. 1998;21:1904-1909.
51. Herbst KL, Hirsch IB. Insulin strategies for primary care providers. Clin Diabetes. 2002;20:11-17.
52. Chantelau E, Schiffers T, Schutze J, Hansen B. Effect of patient-selected intensive insulin therapy on quality of life. Patient Educ Couns. 1997;30:167-173.